Endothelial cells support persistent gammaherpesvirus 68 infection.
A variety of human diseases are associated with gammaherpesviruses, including neoplasms of lymphocytes (e.g. Burkitt's lymphoma) and endothelial cells (e.g. Kaposi's sarcoma). Gammaherpesvirus infections usually result in either a productive lytic infection, characterized by expression of all viral genes and rapid cell lysis, or latent infection, characterized by limited viral gene expression and no cell lysis. Here, we report characterization of endothelial cell infection with murine gammaherpesvirus 68 (gammaHV68), a virus phylogenetically related and biologically similar to the human gammaherpesviruses. Endothelial cells supported gammaHV68 replication in vitro, but were unique in that a significant proportion of the cells escaped lysis, proliferated, and remained viable in culture for an extended time. Upon infection, endothelial cells became non-adherent and altered in size, complexity, and cell-surface protein expression. These cells were uniformly infected and expressed the lytic transcription program based on detection of abundant viral gene transcripts, GFP fluorescence from the viral genome, and viral surface protein expression. Additionally, endothelial cells continued to produce new infectious virions as late as 30 days post-infection. The outcome of this long-term infection was promoted by the gammaHV68 v-cyclin, because in the absence of the v-cyclin, viability was significantly reduced following infection. Importantly, infected primary endothelial cells also demonstrated increased viability relative to infected primary fibroblasts, and this increased viability was dependent on the v-cyclin. Finally, we provide evidence for infection of endothelial cells in vivo in immune-deficient mice. The extended viability and virus production of infected endothelial cells indicated that endothelial cells provided a source of prolonged virus production and identify a cell-type specific adaptation of gammaherpesvirus replication. While infected endothelial cells would likely be cleared in a healthy individual, persistently infected endothelial cells could provide a source of continued virus replication in immune-compromised individuals, a context in which gammaherpesvirus-associated pathology frequently occurs.
Suárez
Andrea Luísa
AL
Department of Microbiology and Program in Molecular Biology, University of Colorado Denver School of Medicine, Aurora, Colorado, United States of America.
van Dyk
Linda Faye
LF
D000818:Animals; D002460:Cell Line; D002470:Cell Survival; D002478:Cells, Cultured; D016213:Cyclins; D042783:Endothelial Cells / Q000473:pathology / Q000821:virology*; D005347:Fibroblasts / Q000473:pathology / Q000821:virology; D006566:Herpesviridae Infections / Q000473:pathology*; D051379:Mice; D008969:Molecular Sequence Data; D018144:Rhadinovirus; D014412:Tumor Virus Infections / Q000473:pathology*; D014764:Viral Proteins; D014779:Virus Replication
D016213:Cyclins; D014764:Viral Proteins
J Virol. 2007 Mar;81(5):2095-101
16956936
J Virol. 2006 Dec;80(24):11946-59
17005668
Philos Trans R Soc Lond B Biol Sci. 2001 Apr 29;356(1408):581-93
11313013
Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7508-13
10377445
Trends Microbiol. 1998 Jul;6(7):276-82
9717216
J Virol. 2000 Aug;74(15):6964-74
10888635
J Virol. 1999 May;73(5):4181-7
10196314
Hum Pathol. 1984 May;15(5):430-9
6327494
Curr Opin Microbiol. 1999 Aug;2(4):403-9
10458986
Am J Gastroenterol. 1985 May;80(5):355-60
2859801
J Virol. 2003 Sep;77(17):9669-84
12915579
Nat Med. 1995 Dec;1(12):1274-8
7489408
Circ Res. 2007 Feb 2;100(2):158-73
17272818
Virol J. 2005 Feb 10;2:7
15705200
FASEB J. 2006 Jun;20(8):1045-54
16770003
J Cell Physiol. 1988 Oct;137(1):75-85
3170659
Virology. 2004 Oct 10;328(1):7-18
15380353
Acta Virol. 1980 Dec;24(6):468
6111210
Viral Immunol. 2004;17(2):308-14
15279708
J Virol. 1997 Aug;71(8):5894-904
9223479
Eur J Immunol. 1996 Feb;26(2):449-53
8617317
J Gen Virol. 1997 Jul;78 ( Pt 7):1675-87
9225045
J Virol. 2003 May;77(9):5118-26
12692214
J Cell Mol Med. 2008 Oct;12(5B):1974-89
18194452
J Virol. 2004 Apr;78(8):4278-88
15047841
J Virol. 2002 Jun;76(11):5522-31
11991980
J Virol. 2004 Feb;78(3):1063-8
14722261
Cancer Cell. 2007 Mar;11(3):245-58
17349582
Nat Immunol. 2002 Aug;3(8):733-40
12101398
J Virol. 2002 Mar;76(5):2440-8
11836422
Scand J Infect Dis Suppl. 1995;99:34-40
8668941
Am J Pathol. 1989 Jan;134(1):223-30
2536523
J Immunol. 1994 Jun 1;152(11):5208-19
7514631
J Exp Med. 1998 Jun 15;187(12):1941-51
9625754
Circulation. 2000 Aug 15;102(7):779-85
10942747
J Virol. 1996 Jun;70(6):3528-35
8648686
J Virol. 2004 Jan;78(1):197-205
14671101
Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10623-8
12963823
PLoS One. 2008 Jan 30;3(1):e1520
18231605
J Virol. 2007 May;81(10):5079-90
17329329
J Immunol. 2004 Sep 15;173(6):3581-8
15356100
Blood. 2006 Jul 1;108(1):141-51
16543476
Philos Trans R Soc Lond B Biol Sci. 2001 Apr 29;356(1408):569-79
11313012
J Gen Virol. 1995 Apr;76 ( Pt 4):741-50
9049319
J Virol. 1996 Oct;70(10):6775-80
8794315
J Exp Med. 2004 Aug 2;200(3):391-8
15289507
J Virol. 2000 Aug;74(16):7451-61
10906198
J Virol. 1999 Aug;73(8):6892-902
10400787
J Virol. 1996 Sep;70(9):6516-8
8709292
J Virol. 2006 Dec;80(23):11539-55
16987970
J Virol. 2004 Dec;78(23):13370-5
15542690
Nature. 1998 Aug 6;394(6693):588-92
9707121
EMBO J. 2002 May 15;21(10):2418-29
12006494
J Immunol Methods. 2000 Oct 20;244(1-2):205-15
11033033
PLoS Pathog. 2006 Oct;2(10):e107
17238276
J Virol. 1987 Jul;61(7):2198-207
3035220
J Virol. 1998 Jul;72(7):5661-8
9621025
Circ Res. 2007 Feb 2;100(2):174-90
17272819
J Virol. 1993 Sep;67(9):5247-52
8394447
Science. 1994 Jul 15;265(5170):391-4
8023160
Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3805-10
15738413
Cancer Res. 2001 Mar 15;61(6):2641-8
11289142
Blood. 2006 Sep 15;108(6):1932-40
16601245
Cancer Cell. 2006 Aug;10(2):133-43
16904612
J Virol. 2002 Jul;76(14):7125-32
12072512
Trends Cardiovasc Med. 2005 Jul;15(5):174-84
16165014
Nat Genet. 2004 Jul;36(7):683-5
15220917
J Immunol. 2004 Mar 15;172(6):3850-9
15004192
Cancer Cell. 2003 Jan;3(1):23-36
12559173
J Immunol Methods. 2003 Dec;283(1-2):307-15
14659921
Nat Genet. 2004 Jul;36(7):687-93
15220918
J Virol. 2004 May;78(10):5103-12
15113892
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3366-71
17360652
J Virol. 1999 Jun;73(6):5110-22
10233974
Curr Opin Microbiol. 2002 Aug;5(4):403-7
12160860
J Virol. 2001 Jun;75(12):5614-26
11356969
J Exp Med. 1979 Sep 19;150(3):580-96
90108
J Immunol. 1989 Oct 15;143(8):2714-22
2794510
Cancer Res. 1990 Dec 1;50(23):7686-96
2253213
Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):690-4
9012846